US2022389029A1PendingUtilityA1
Fused pyridone compound, and preparation method therefor and use thereof
Assignee: SHANGHAI JEMINCARE PHARMACEUTICALS CO LTDPriority: Sep 20, 2019Filed: Sep 21, 2020Published: Dec 8, 2022
Est. expirySep 20, 2039(~13.2 yrs left)· nominal 20-yr term from priority
C07D 498/14C07D 498/22A61P 35/00C07D 471/14C07D 471/22A61K 31/553A61K 31/5383A61K 31/4985C07D 513/22C07D 491/147A61P 1/18A61P 1/00A61P 11/00
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed in the present invention are a fused pyridone compound, and a preparation method therefor and a use thereof. Specifically, the present invention discloses a compound of formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.
Claims
exact text as granted — not AI-modified1 . A compound represented by formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof,
wherein,
R 1 , R 2 are independently selected from H, halogen and C 1-6 alkyl, the C 1-6 alkyl is optionally substituted by 1, 2 or 3 R;
R 3 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— and C 3-6 cycloalkyl-O—, the C 1-6 alkyl, C 1-6 heteroalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— or C 3-6 cycloalkyl-O— is optionally substituted by 1, 2 or 3 R;
R 4 is independently selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl or 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
R 5 is selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, 3-8 membered heterocycloalkyl, phenyl, naphthyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl, the C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, 3-8 membered heterocycloalkyl, phenyl, naphthyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl or 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
L 1 is selected from —C(═O)—, —S(═O)— and —S(═O) 2 —;
R 6 is selected from H, CN, C 1-6 alkyl, C 1-6 alkyl-S(═O) 2 —, 3-6 membered heterocycloalkyl, —C 1-6 alkyl-3-6 membered heterocycloalkyl and C 3-6 cycloalkyl-C(═O)—, the C 1-6 alkyl, C 1-6 alkyl-S(═O) 2 —, 3-6 membered heterocycloalkyl, —C 1-6 alkyl-3-6 membered heterocycloalkyl or C 3-6 cycloalkyl-C(═O)— is optionally substituted by 1, 2 or 3 R;
R 7 is independently selected from H, halogen, OH, NH 2 , CN, —C(═O)—OH, C 1-6 alkyl-O—C(═O)—, —C(═O)—NH 2 , C 1-6 alkyl, C 1-6 heteroalkyl and —C 1-6 alkyl-3-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 1-6 alkyl-O—C(═O)— or —C 1-6 alkyl-3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
T 1 , T 2 are independently selected from N and —C(R 8 )—;
R 8 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
R 9 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl and C 1-6 heteroalkyl, the C 1-6 alkyl or C 1-6 heteroalkyl is optionally substituted by 1, 2 or 3 R;
R 10 is selected from H, halogen, CN, C 1-6 alkyl, C 1-6 alkoxy and C 1-6 alkylamino, the C 1-6 alkyl, C 1-6 alkoxy or C 1-6 alkylamino is optionally substituted by 1, 2 or 3 R;
R is independently selected from H, halogen, OH, NH 2 , CN,
C 1-6 alkyl, C 1-6 heterocycloalkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl, C 3-6 cycloalkyl-O— and 5-6 membered heterocycloalkyl-O—, the C 1-6 alkyl, C 1-6 heterocycloalkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl, C 3-6 cycloalkyl-O— or 5-6 membered heterocycloalkyl-O— is optionally substituted by 1, 2 or 3 R′;
R′ is selected from F, Cl, Br, I, OH, NH 2 and CH 3 ;
ring A is independently selected from C 6-10 aryl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl;
n is selected from 0, 1, 2, 3 or 4;
m is selected from 0, 1, 2, 3 or 4;
D 1 is selected from O;
Y is selected from N, CH or C;
is or , and when is , R 2 , R 10 are not existed;
is or ;
when in , is , X 1 , X 2 are independently selected from —N═, —C(R 7 )═ and —C(R 7 ) 2 —C(R 7 )═;
when in , is , X 1 , X 2 are independently selected from single bond, —O—, —S—, S(═O), S(═O) 2 , —N(R 6 )—, —C(═O)—, —C(R 7 ) 2 — and —C(R 7 ) 2 —C(R 7 ) 2 —;
and, Y cannot be connected to two at the same time, when the bond between Y and R 9 is , R 9 is not existed;
the above 3-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocycloalkyl, 5-10 membered heteroaryl or C 1-6 heterocycloalkyl comprises 1, 2, or 3 heteroatoms or heteroatomic groups independently selected from —O—, —NH—, —S—, —C(═O)—, —C(═O)O—, —S(═O)—, —S(═O) 2 and N.
2 . A compound represented by formula (I-A), an optical isomer thereof and a pharmaceutically acceptable salt thereof,
wherein,
R 1 , R 2 are independently selected from H, halogen and C 1-6 alkyl, the C 1-6 alkyl is optionally substituted by 1, 2 or 3 R;
R 3 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— and C 3-6 cycloalkyl-O—, the C 1-6 alkyl, C 1-6 heteroalkyl, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— or C 3-6 cycloalkyl-O— is optionally substituted by 1, 2 or 3 R;
R 4 is independently selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl or 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
R 5 is selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, 3-8 membered heterocycloalkyl, phenyl, naphthyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl, the C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, 3-8 membered heterocycloalkyl, phenyl, naphthyl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl or 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
L 1 is selected from —C(═O)—, —S(═O)— and —S(═O) 2 —;
R 6 is selected from H, CN, C 1-6 alkyl, C 1-6 alkyl-S(═O) 2 —, 3-6 membered heterocycloalkyl, —C 1-6 alkyl-3-6 membered heterocycloalkyl and C 3-6 cycloalkyl-C(═O)—, the C 1-6 alkyl, C 1-6 alkyl-S(═O) 2 —, 3-6 membered heterocycloalkyl, —C 1-6 alkyl-3-6 membered heterocycloalkyl or C 3-6 cycloalkyl-C(═O)— is optionally substituted by 1, 2 or 3 R;
R 7 is independently selected from H, halogen, OH, NH 2 , CN, —C(═O)OH, C 1-6 alkyl-O—C(═O)—, —C(═O)—NH 2 , C 1-6 alkyl, C 1-6 heteroalkyl and —C 1-6 alkyl-3-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 1-6 alkyl-O—C(═O)— or —C 1-6 alkyl-3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
T 1 , T 2 are independently selected from N and —C(R 8 )—;
R 8 is selected from H, halogen, OH, NH 2 , CN, C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl and 3-6 membered heterocycloalkyl, the C 1-6 alkyl, C 1-6 heteroalkyl, C 3-6 cycloalkyl or 3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R;
R is independently selected from H, halogen, OH, NH 2 , CN
C 1-6 alkyl, C 1-6 heterocycloalkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl, C 3-6 cycloalkyl-O— and 5-6 membered heterocycloalkyl-O—, the C 1-6 alkyl, C 1-6 heterocycloalkyl, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl, C 3-6 cycloalkyl-O— or 5-6 membered heterocycloalkyl-O— is optionally substituted by 1, 2 or 3 R′;
R′ is selected from F, Cl, Br, I, OH, NH 2 and CH 3 ;
ring A is independently selected from C 6-10 aryl, 5-10 membered heteroaryl, benzo 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl-fused 5-6 membered heterocycloalkyl;
n is selected from 0, 1, 2, 3 or 4;
is or , and when is , R 2 is not existed;
is or ;
when in , is , X 1 , X 2 are independently selected from —N═, —C(R 7 )═ and —C(R 7 ) 2 —C(R 7 )═;
when in , is , X 1 , X 2 are independently selected from single bond, —O—, —S—, S(═O), S(═O) 2 , —N(R 6 )—, —C(═O)—, —C(R 7 ) 2 — and —C(R 7 ) 2 —C(R 7 ) 2 —;
the above 3-6 membered heterocycloalkyl, 5-6 membered heteroaryl, 5-6 membered heterocycloalkyl, 5-10 membered heteroaryl or C 1-6 heterocycloalkyl comprises 1, 2, or 3 heteroatoms or heteroatomic groups independently selected from —O—, —NH—, —S—, —C(═O)—, —C(═O)O—, —S(═O)—, —S(═O) 2 and N.
3 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 or 2 , selecting from
wherein,
X 1 , X 2 are independently selected from single bond, —O—, —S—, S(═O), S(═O) 2 , —N(R 6 )—, —C(═O)—, —C(R 7 ) 2 — and —C(R 7 ) 2 —C(R 7 ) 2 —,
R 1 , R 2 , R 3 , R 4 , R 5 , L 1 , R 6 , R 7 , T 1 , T 2 , ring A and n are as defined in claim 1 or 2 .
4 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 3 , wherein, R is independently selected from H, halogen, OH, NH 2 , CN,
C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio, C 1-3 alkylamino, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl, C 3-6 cycloalkyl-O— and -5-6 membered heterocycloalkyl-O—, the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio, C 1-3 alkylamino, C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl, C 3-6 cycloalkyl-O— or 5-6 membered heterocycloalkyl-O— is optionally substituted by 1, 2 or 3 R′.
5 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 4 , wherein, R is independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CH 2 CH 3 ,
6 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 or 2 , wherein, R 1 , R 2 are independently selected from H, F, Me, CF 3 ,
7 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 6 , wherein, the structural moiety
is selected from
8 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 or 2 , wherein, R 3 is selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— and C 3-6 cycloalkyl-O—, the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio, 3-6 membered heterocycloalkyl, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl-O— or C 3-6 cycloalkyl-O— is optionally substituted by 1, 2 or 3 R.
9 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 8 , wherein, R 3 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 ,
10 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 or 2 , wherein, R 4 is independently selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, pyridinyl, pyrimidinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzofuranyl, benzothienyl and indolyl, the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio, C 3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl, pyridinyl, pyrimidinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzofuranyl, benzothienyl or indolyl is optionally substituted by 1, 2 or 3 R.
11 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 10 , wherein, R 4 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 ,
12 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 or 2 , wherein, ring A is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoimidazolyl, 1H-benzo[d]imidazolyl, benzopyrazolyl, purinyl, quinolinyl, isoquinolinyl, isoquinolin-1(2H)-one, isoindolin-1-one, benzo[d]oxazol-2(H)-one, benzo[d]oxazol-2(3H)-one, H-benzo[d] [1,2,3]triazolyl, 1H-pyrazolo[3,4-b]pyridinyl, benzo[d]thiazolyl and 1,3-dihydro-2H-benzo[d]imidazolyl-2-one, the phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzofuranyl, benzothienyl, indolyl, indazolyl, benzoimidazolyl, 1H-benzo[d]imidazolyl, benzopyrazolyl, purinyl, quinolinyl, isoquinolinyl, isoquinolin-1(2H)-one, isoindolin-1-one, benzo[d]oxazol-2(H)-one, benzo[d]oxazol-2(3H)-one, H-benzo[d] [1,2,3]triazolyl, 1H-pyrazolo[3,4-b]pyridinyl, benzo[d]thiazolyl or 1,3-dihydro-2H-benzo[d]imidazolyl-2-one is optionally substituted by 1, 2 or 3 R.
13 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 12 , wherein, the structural moiety
is selected from
14 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 or 2 , wherein, R 5 is selected from H, C 1-3 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydro-2H-pyranyl, piperidinyl, piperazinyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzofuranyl, benzothienyl, indolyl, benzoimidazolyl, benzopyrazolyl, purinyl, quinolinyl, isoquinolinyl, isoquinolin-1(2H)-one, isoindolin-1-one, benzo[d]oxazol-2(H)-one and 1,3-dihydro-2H-benzo[d]imidazolyl-2-one, the C 1-3 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydro-2H-pyranyl, piperidinyl, piperazinyl, 5-6 membered heterocycloalkyl-C 1-3 alkyl-, phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzofuranyl, benzothienyl, indolyl, benzoimidazolyl, benzopyrazolyl, purinyl, quinolinyl, isoquinolinyl, isoquinolin-1(2H)-one, isoindolin-1-one, benzo[d]oxazol-2(H)-one or 1,3-dihydro-2H-benzo[d]imidazolyl-2-one is optionally substituted by 1, 2 or 3 R.
15 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 14 , wherein, R 5 is selected from H, Me,
16 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 or 2 , wherein, R 7 is independently selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkyl-O—C(═O)—, —C(═O)—NH 2 , C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio and —C 1-3 alkyl-3-6 membered heterocycloalkyl, the C 1-3 alkyl, C 1-3 alkyl-O—C(═O)—, —C(═O)—NH 2 , C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 alkylthio or —C 1-3 alkyl-3-6 membered heterocycloalkyl is optionally substituted by 1, 2 or 3 R.
17 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 16 , wherein, R 7 is independently selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 ,
18 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 or 2 , wherein, R 6 is independently selected from H, CN, C 1-3 alkyl, C 1-3 alkyl-S(═O) 2 —, 3-6 membered heterocycloalkyl, —C 1-3 alkyl-3-6 membered heterocycloalkyl and C 3-6 cycloalkyl-C(═O)—, the C 1-3 alkyl, C 1-3 alkyl-S(═O) 2 —, 3-6 membered heterocycloalkyl, —C 1-3 alkyl3-6 membered heterocycloalkyl or C 3-6 cycloalkyl-C(═O)— is optionally substituted by 1, 2 or 3 R.
19 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 18 , wherein, R 6 is independently selected from H, CN, Me, CF 3 ,
20 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 18 , wherein, X 1 , X 2 are independently selected from single bond, CH 2 , CH 2 CH 2 , C(═O), O, S, NH, N(CH 3 ), S(═O), S(═O) 2 ,
21 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 or 2 , wherein, R 8 is selected from H, halogen, OH, NH 2 , CN, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino and C 1-3 alkylthio, the C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamino or C 1-3 alkylthio is optionally substituted by 1, 2 or 3 R.
22 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 21 , wherein, R 8 is selected from H, F, Cl, Br, I, OH, NH 2 , CN, Me, CF 3 ,
23 . The compound, the optical isomer thereof and the pharmaceutically acceptable salt thereof according to claim 1 , wherein, the structural moiety
is selected from
24 . Compounds of the following formula, optical isomers thereof and pharmaceutically acceptable salts thereof,
25 . A pharmaceutical composition, comprising the compound, the optical isomer and the pharmaceutically acceptable salt thereof as defined in claims 1 or 2 , and one or more pharmaceutically acceptable carriers, diluents or excipients.
26 . A method of preventing and/or treating diseases related to KRAS-G12C, comprising administering to a patient in need thereof a pharmaceutically effective amount of compound of claim 1 or claim 2 or a pharmaceutical composition of claim 25 .
27 . The method according to claim 26 , wherein the diseases related to KRAS-G12C are selected from non-small cell lung cancer, colon cancer and pancreatic cancer.Join the waitlist — get patent alerts
Track US2022389029A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.